urotronic Archives - Medical Design Sourcing

Laborie acquires drug-coated balloon maker Urotronic

The Optilume BPH catheter system drug-coated balloon. [Image courtesy of Urotronic]Laborie Medical Technologies announced today that it completed the acquisition of drug-coated balloon developer Urotronic.

The companies struck an agreement last month for Laborie to buy Urotronic for up to $600 million.

Urotronic developed the Optilume DCB used in interventional urology procedures. It treats urethral strictures and benign prostatic hyperplasia (BPH) or enlarged prostate conditions.

Minneapolis-based Laborie acquired exclusive rights to Optilume in January 2022. The system combines mechanical dilation using a proprietary double-lobe balloon with concurrent localized delivery of paclitaxel.

Under the terms of the acquisition, Laborie intends to pay $255 million upfront in cash. It also includes up to $345 million in potential commercial and reimbursement milestones. Net of Laborie’s existing minority investment in Urotronic, the deal comes to $232…

FDA approves drug-coated balloon for BPH symptoms from Urotronic

The Optilume BPH catheter system drug-coated balloon. [Image courtesy of Urotronic]Urotronic announced that the FDA approved its Optilume BPH catheter system for to alleviate urinary symptoms caused by BPH.

Minneapolis-based Urotronic designed Optilume as a minimally invasive surgical therapy. It combines mechanical dilation using a proprietary double-lobe balloon with concurrent localized delivery of paclitaxel. This treats lower urinary tract symptoms secondary to BPG (benign prostatic hyperplasia).

Urotronic previously received FDA approval Optilume for the treatment of male urethral strictures. In these cases, the balloon inhibits new scar tissue growth that can occur after endoscopic dilations.

Get the full story at our sister site, Medical Tubing & Extrusion.

Laborie acquires exclusive license for drug-coated baloon treatment for urethral strictures

Laborie Medical Technologies announced today that it acquired an exclusive license to the Optilume urethral drug-coated balloon (DCB).

Portsmouth, New Hampshire-based Laborie purchased a perpetual, exclusive license to Optilume — developed by Urotronic — following FDA approval in December 2021. The DCB platform received CE mark approval for use in male anterior urethral strictures in 2020.

Get the full story at our sister site, Drug Delivery Business News.

FDA approves Urotronic’s Optilume drug coated balloon for urethral strictures

Urotronic today announced that it received FDA approval for its Optilume urethral drug coated balloon for male urethral strictures.

Minneapolis-based Urotronic designed the paclitaxel-coated balloon to inhibit new scar tissue growth that can occur after endoscopic dilations. Urethral strictures are scars in or around the urethra that can restrict the flow of urine from the bladder.

Get the full story on our sister site, Medical Tubing + Extrusion.